Beatriz Vidaña1,2, Sharon M Brookes3, Helen E Everett3, Fanny Garcon3,4, Alejandro Nuñez2, Othmar Engelhardt5, Diane Major5, Katja Hoschler6, Ian H Brown3, Maria Zambon6. 1. Bristol Veterinary School, Faculty of Health Science, University of Bristol, Bristol, UK. 2. Pathology Department, Animal and Plant Health Agency, APHA-Weybridge, Addlestone, UK. 3. Virology Department, Animal and Plant Health Agency, APHA-Weybridge, Addlestone, UK. 4. Laboratoires Théa, Clermont-Ferrand, France. 5. National Institute for Biological Standards and Control, Potters Bar, UK. 6. Public Health England - Colindale, London, UK.
Abstract
BACKGROUND: The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza A virus (IAV) has replaced the previous seasonal H1N1 strain in humans and continues to circulate worldwide. The comparative performance of inactivated A(H1N1)pdm09 influenza vaccines remains of considerable interest. The objective of this study was to evaluate the efficacy of two licensed A(H1N1)pdm09 inactivated vaccines (AS03B adjuvanted split virion Pandemrix from GlaxoSmithKline and referred here as (V1) and non-adjuvanted whole virion Celvapan from Baxter and referred here as (V2)) in ferrets as a pre-clinical model for human disease intervention. METHODS: Naïve ferrets were divided into two groups (V1 and V2) and immunised intramuscularly with two different A/California/07/2009-derived inactivated vaccines, V1 administered in a single dose and V2 administered in 2 doses separated by 21 days. Six weeks after the first immunisation, vaccinated animals and a non-vaccinated control (NVC) group were intra-nasally challenged with 106.5 TCID50 of the isolate A/England/195/2009 A(H1N1)pdm09 with 99.1% amino acid identity to the vaccine strain. Clinical signs, lung histopathology, viral quantification and antibody responses were evaluated. RESULTS AND CONCLUSIONS: Results revealed important qualitative differences in the performance of both inactivated vaccines in relation to protection against challenge with a comparable virus in a naive animal (ferret) model of human disease. Vaccine V1 limited and controlled viral shedding and reduced lower respiratory tract infection. In contrast, vaccine V2 did not control infection and animals showed sustained viral shedding and delayed lower respiratory infection, resulting in pulmonary lesions, suggesting lower efficacy of V2 vaccine.
BACKGROUND: The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza A virus (IAV) has replaced the previous seasonal H1N1 strain in humans and continues to circulate worldwide. The comparative performance of inactivated A(H1N1)pdm09 influenza vaccines remains of considerable interest. The objective of this study was to evaluate the efficacy of two licensed A(H1N1)pdm09 inactivated vaccines (AS03B adjuvanted split virion Pandemrix from GlaxoSmithKline and referred here as (V1) and non-adjuvanted whole virion Celvapan from Baxter and referred here as (V2)) in ferrets as a pre-clinical model for human disease intervention. METHODS: Naïve ferrets were divided into two groups (V1 and V2) and immunised intramuscularly with two different A/California/07/2009-derived inactivated vaccines, V1 administered in a single dose and V2 administered in 2 doses separated by 21 days. Six weeks after the first immunisation, vaccinated animals and a non-vaccinated control (NVC) group were intra-nasally challenged with 106.5 TCID50 of the isolate A/England/195/2009 A(H1N1)pdm09 with 99.1% amino acid identity to the vaccine strain. Clinical signs, lung histopathology, viral quantification and antibody responses were evaluated. RESULTS AND CONCLUSIONS: Results revealed important qualitative differences in the performance of both inactivated vaccines in relation to protection against challenge with a comparable virus in a naive animal (ferret) model of human disease. Vaccine V1 limited and controlled viral shedding and reduced lower respiratory tract infection. In contrast, vaccine V2 did not control infection and animals showed sustained viral shedding and delayed lower respiratory infection, resulting in pulmonary lesions, suggesting lower efficacy of V2 vaccine.
Authors: Benoît Baras; Leon de Waal; Koert J Stittelaar; Valérie Jacob; Sandra Giannini; Edwin J B Veldhuis Kroeze; Judith M A van den Brand; Geert van Amerongen; James H Simon; Emmanuel Hanon; Sally P Mossman; Albert D M E Osterhaus Journal: Vaccine Date: 2011-01-14 Impact factor: 3.641
Authors: Timo Vesikari; Jan Hendrik Richardus; Johan Berglund; Tiina Korhonen; Carl-Erik Flodmark; Ann Lindstrand; Sven Arne Silfverdal; Vinod Bambure; Adrian Caplanusi; Ilse Dieussaert; Sumita Roy-Ghanta; David W Vaughn Journal: Pediatr Infect Dis J Date: 2015-07 Impact factor: 2.129
Authors: Claire S Waddington; W T Walker; C Oeser; A Reiner; T John; S Wilkins; M Casey; P E Eccleston; R J Allen; I Okike; S Ladhani; E Sheasby; K Hoschler; N Andrews; P Waight; A C Collinson; P T Heath; A Finn; S N Faust; M D Snape; E Miller; A J Pollard Journal: BMJ Date: 2010-05-27
Authors: Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen Journal: Clin Vaccine Immunol Date: 2012-05-09
Authors: Brandon Z Löndt; Sharon M Brookes; Bethany J Nash; Alejandro Núñez; David A Stagg; Ian H Brown Journal: Influenza Other Respir Viruses Date: 2012-06-21 Impact factor: 4.380
Authors: Beatriz Vidaña; Sharon M Brookes; Helen E Everett; Fanny Garcon; Alejandro Nuñez; Othmar Engelhardt; Diane Major; Katja Hoschler; Ian H Brown; Maria Zambon Journal: Influenza Other Respir Viruses Date: 2020-08-11 Impact factor: 4.380
Authors: Beatriz Vidaña; Sharon M Brookes; Helen E Everett; Fanny Garcon; Alejandro Nuñez; Othmar Engelhardt; Diane Major; Katja Hoschler; Ian H Brown; Maria Zambon Journal: Influenza Other Respir Viruses Date: 2020-08-11 Impact factor: 4.380